Default company panoramic image
Heragen 20final


We are a startup aspiring to develop and commercialize a first-in-class In Vitro Diagnostics kit with predictive and prognostic capabilities for breast cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, US
  • Currency USD
  • Founded March 2014
  • Employees 2
  • Website

Company Summary

We aspire to develop and commercialize a first-in-class FDA-approved In Vitro Diagnostics kit with predictive and prognostic capabilities for breast cancer. Unlike our main competitors, Oncotype Dx and Mammaprint, our product will allow cancer centers, hospitals, and research centers to run the test in their facilities. Furthermore, pre-clinical data suggests that this technology can be used in any breast cancer type.


  • 27a362d

    Gerardo Ramirez’s experience in diagnostics started at Ambry Genetics, developing collaborations with biotechs, working with Marketing and Business Development teams to increase revenues, and improving operational processes. His background includes managing projects for public and private institutions, most recently as Project Manager for DOE’s JGI. He received a BS in Biology and MS in Biochemistry and Molecular Biology from UC Riverside.

  • Test3

    Mr. Chandramohan developed the business strategy and plan for an algae-based nutraceuticals and biofuels project focussing on carotenoids production from salt water algae. Mr. Chandramohan’s experience includes bioinformatics analysis and pipeline development at DOE’s Joint Genome Institute (JGI) – Lawrence Berkeley National Laboratory (LBNL). He received a MS in Computational Biology from Carnegie Mellon University.


  • E3855924 aa83 4f27 b39d 37329583d6cc
    Scientific Advisor
    Default avatar
    Russell Schwartz
    Scientific Advisor